Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug ...

NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12.00 in a report issued on Tuesday,Benzinga reports. The firm presently has ...

(“Fortrea” or the “Company”) (NASDAQ: FTRE) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON FORTREA ...

Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to $15.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently ...

Group net income of EUR 233 million in Q4 2024 driven by all business activities (EUR 235 million adjusted 1) P&C combined ratio of 83.1% in Q4 2024 including a low Nat Cat ratio and allowing for ...

Fortrea Holdings Inc. has recently released its 10-K report, providing a detailed insight into its financial performance and operations. The company, a leading global contract research organization, ...

Cruz announces an investigation of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) on behalf of investors concerning the Company’s possible violations of federal ...

SG&A Increase: 16.9% year over year for Q4 2024. Net Interest Expense: $21.9 million for Q4 2024, a decrease of $12.6 million year over year. Fortrea Holdings Inc (NASDAQ:FTRE) achieved a strong ...